Melania Trump used to walk red carpets in sparkly, sheer outfits. As first lady, she embraces suits, high-fashion designers, ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Copyright 2025 The Associated Press. All Rights Reserved. Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] The AP Top 25 men’s college ...

Eli Lilly has received approval from the US Food and Drug Administration ... had an insufficient response or intolerance to standard treatments. The VIVID-1 trial met both primary endpoints: clinical ...

The FDA ap­proved Eli Lil­ly’s Omvoh in Crohn’s dis­ease, the com­pa­ny an­nounced Wednes­day, hand­ing the drug its sec­ond in­di­ca­tion af­ter giv­ing it a green light … ...

John Beggs KC, leading the Met’s legal team, said the case raised the “fundamental issue” of whether a chief officer is entitled to sack officers who cannot clear the basic vetting procedures.

OnlyFans stars Lilly Phillips and Bonnie Blue are vying to have sex with more men, a feud that drove social media crazy back in 2024, when Phillips met the challenge of sleeping with 100 men in 24 ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her Endpoints News story about the case. Lilly’s lawsuit ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...